Directrice générale CEO
Alga Biologics
Alga Biologics utilizes a patented microalgae-based platform to produce recombinant proteins and antibodies with human-like glycosylation, ensuring high quality and stability while eliminating the risk of viral contamination. Their technology significantly reduces production costs by up to 70% and provides a sustainable alternative to traditional animal-derived methods in the biopharmaceutical industry.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Features
- Alga Biologics utilizes a patented microalgae-based platform to produce recombinant proteins and antibodies with human-like glycosylation, ensuring high quality and stability while eliminating the risk of viral contamination. Their technology significantly reduces production costs by up to 70% and provides a sustainable alternative to traditional animal-derived methods in the biopharmaceutical industry.